The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Summary:
Using a novel protein-structure-based B cell epitope discovery method with a wide range of possible applications, we have identified a simple to measure host-pathogen antibody signature associated with severe COVID-19 and longCOVID and suggest the viral Membrane protein contains an epitope that acts as a T independent antigen during infection triggering extrafollicular B cell activation.
Structural epitope profiling identifies antibodies associated with critical COVID-19 and long COVID
https://www.medrxiv.org/content/10.1101/2022.07.11.22277368v4
Where does it mention Synairgen?
Here
“Precision medicine for pandemics: stratification of COVID-19”
And Here
Together with Scientists from Medicine and Biological Sciences and University spin out company, Synairgen, TopMD will lead molecular phenotyping in a €14m EU-funded international consortium for COVID-19 advanced diagnostics.
TopMD co-founders, James Schofield, Lecturer in Systems Biomedicine and Paul Skipp, Associate Professor in Proteomics will work with a number of other University of Southampton researchers and academics in leading the DRAGON project.
And Here
“A significant proportion of medical research seeks to better understand
complex, heterogeneous patient and population groups, and to divide them
into subclasses defined by markers.
Stratified, precision, P4 or personalised medicine has the ultimate goal to
ensure that the right patient receives the right therapy at the right time“
https://synairgen.ams3.digitaloceanspaces.com/230629-Synairgen-AGM-2023_FINAL.pdf
Synairgen have always been in the foreground of this kind of collaborative process.
It seems one of the many interests are co founder has is
Precision medicine for pandemics!
I wonder who else in BP and world government organisations might have similar interests?
What is a great shame is the person who did find this information gets ridiculed by the idiot who has so after ridiculed that group but then goes on to pontificate about it’s importance
“whoever found it on Reddit. Twitter finds used to be pmjh'speciality. - sitting in his basement”
Thanks for the link Brysoa
Most intriguing that they sponsor a piece of work that they themselves have already done and presented on.
Why would you do that and why would UKHSA be interested unless there’s a conversation in the background #100DM
https://www.gov.uk/government/publications/100-days-mission-uk-specific-report-for-2022/100dm-how-the-uk-is-contributing-to-the-global-mission-to-develop-pandemic-fighting-tools-within-100-days
The key here is NOT who’s test is being used.
They’re presenting on pandemic preparedness and variant escape. Highlighting how monoclonals had been escaped and therapeutics remain limited.
They chose our drug to use as an example
Good question Brand
Seems it’s part of the newly created
The Vaccine Development Evaluation Centre (VDEC) at Porton Down in Wiltshire facilitates the development and evaluation of new vaccines and therapeutics.
I don’t think we’ve seen Synairgen independently tested and presented by a government body before. This appears to be instigated and chosen by this body as an example for pandemic preparedness and for its agnostic benefits. Most of the presentation team for this abstract are UKHSA
Great find
The final paragraph is quite interesting as are the people leading the presenting - Government agency UKHSA (Amanda Horton) and of course the compound they chose to present on
A368
The antiviral efficacy of interferon-β1a (SNG001) against different SARS-CoV-
2 variants, in vitro.
Amanda Horton1, Sarah Dudley2, Matthew Wand1, Daniel Packham1, Irene CanoCejas1, Victoria
Tear2, Phillip Monk2, Mark Sutton1, Julia Tree1
1UKHSA, Salisbury, United Kingdom. 2Synairgen Research Ltd., Southampton, United Kingdom
Abstract
With the emergence of SARS-CoV-2 variants resistant to monoclonal antibody therapies and limited
global access to therapeutics, the evaluation of novel therapeutics to prevent progression to severe
COVID-19 remains a critical need. Inhaled interferon-β1a (IFN- β1a) (SNG001) is being investigated as
a potential treatment for severe respiratory viral infections including COVID-19. IFN-β1a is a cytokine
that is naturally produced in the lungs, in response to viral infections. Sometimes invading viruses
switch off this mechanism, to enable viral replication allowing the virus to spread. Administering
aerosolised IFN-β1a directly into the lung airways allows for IFN-β1 levels to be restored at the site
of infection and ‘switches on’ antiviral defences. Inhaled IFN-β1a treatment is being developed as a
potential broad-spectrum variant agnostic treatment for severe viral lung infections including those
caused by SARS-CoV-2.
In this study we tested the antiviral efficacy of IFN-β1a, in vitro, against a variety of SARS-CoV-2
variants to provide reassurance that IFN-β1a was effective against the different variants as they
emerged. A 96-well micro-inhibitory, foci reduction assay with VeroE6 cells was used to determine
the amount of IFN-β1a (IU/ml) causing a 50% reduction (IC50) in viral foci compared to the virus only
control.
Results indicate that the in vitro efficacy of IFN-β1a is retained against different SARS-CoV-2 variants
including Alpha, Beta, Delta, Gamma and Omicron BA.2 variants with IC50’s ranging from 2.35 to
14.10 IU/ml.
Here we discuss the importance of continued monitoring of the efficacy of novel and
licensed treatments for COVID-19 and preparedness for future pandemics.
March 2023 Scinv’s Sprinter trial analysis. It was truly comedy gold
Scinv_temp
Posted in: SNG
Posts: 1,028
Price: 7.50
No Opinion
RE: BARDA detailed interests
31 Mar 2023 15:22
Deaths:
Day 7
Sng001 4, placebo 0
Day 14,
Sng001 9, placebo 7
Day 21
Sng001 12, placebo 9
Day 28
Sng001 14, placebo 14
Day 35
Sng001 14, placebo 17.
Total Deaths
Sng001 53, placebo 47
TommyD_19
Posts: 3,083
Price: 7.50
No Opinion
RE: BARDA detailed interests
31 Mar 2023 15:37
Scinv
14 died on drug and 17 on placebo
You’re not meant to add up each week for a grand total you muppet
Wow
The muppet who added up Sprinter trial data to get the wrong calculations for patient numbers being ventilated has returned to tell us all about the science.
When I say returned I obviously mean reusing an old account.